Skip to main content
OpenTrials
Completed

NCT Number: NCT01227369

Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment

Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

GSK Investigational Site

Seoul, 137-701, South Korea

About this study

Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation

Exclusion criteria

  • Do not understand the contents of the questionnaire

Treatment and study plan

OPSAT-Q

Other

A linguistically validated Korean version of OPSAT-Q

Primary outcomes

  1. Mean of composite satisfaction score (CSS) of OPSAT-QTM

    Time frame: 0day

Secondary outcomes

  1. Mean of subscale satisfaction scores of OPSAT-QTM

    Time frame: oday

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Acronym: BRAVO

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Oct 25, 2010
Registry last updated
Jun 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.